- Home
- IMRN vs MYNZ Comparison
IMRN vs MYNZ Comparison
Compare IMRN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- MYNZ
- Stock Information
- Founded
- IMRN 1994
- MYNZ 2021
- Country
- IMRN Australia
- MYNZ Germany
- Employees
- IMRN N/A
- MYNZ N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- MYNZ Health Care
- Exchange
- IMRN Nasdaq
- MYNZ Nasdaq
- Market Cap
- IMRN 9.2M
- MYNZ 7.6M
- IPO Year
- IMRN N/A
- MYNZ 2021
- Fundamental
- Price
- IMRN $1.72
- MYNZ $2.04
- Analyst Decision
- IMRN Strong Buy
- MYNZ Buy
- Analyst Count
- IMRN 1
- MYNZ 2
- Target Price
- IMRN $5.00
- MYNZ $14.00
- AVG Volume (30 Days)
- IMRN 656.2K
- MYNZ 185.7K
- Earning Date
- IMRN 09-08-2025
- MYNZ 08-05-2025
- Dividend Yield
- IMRN N/A
- MYNZ N/A
- EPS Growth
- IMRN N/A
- MYNZ N/A
- EPS
- IMRN N/A
- MYNZ N/A
- Revenue
- IMRN $4,048,286.00
- MYNZ $893,991.00
- Revenue This Year
- IMRN N/A
- MYNZ $26.06
- Revenue Next Year
- IMRN N/A
- MYNZ $4.97
- P/E Ratio
- IMRN N/A
- MYNZ N/A
- Revenue Growth
- IMRN 82.90
- MYNZ N/A
- 52 Week Low
- IMRN $1.50
- MYNZ $1.34
- 52 Week High
- IMRN $2.87
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- IMRN 45.31
- MYNZ 57.11
- Support Level
- IMRN $1.60
- MYNZ $1.89
- Resistance Level
- IMRN $1.80
- MYNZ $2.25
- Average True Range (ATR)
- IMRN 0.10
- MYNZ 0.22
- MACD
- IMRN -0.01
- MYNZ 0.05
- Stochastic Oscillator
- IMRN 34.09
- MYNZ 76.14
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.